Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BASILIXIMAB Cause Hypophosphataemia? 12 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Hypophosphataemia have been filed in association with BASILIXIMAB (Simulect). This represents 0.2% of all adverse event reports for BASILIXIMAB.

12
Reports of Hypophosphataemia with BASILIXIMAB
0.2%
of all BASILIXIMAB reports
0
Deaths
3
Hospitalizations

How Dangerous Is Hypophosphataemia From BASILIXIMAB?

Of the 12 reports, 3 (25.0%) required hospitalization, and 3 (25.0%) were considered life-threatening.

Is Hypophosphataemia Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BASILIXIMAB. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does BASILIXIMAB Cause?

Cytomegalovirus infection (590) Drug ineffective (567) Off label use (567) Transplant rejection (554) Kidney transplant rejection (456) Product use in unapproved indication (428) Pyrexia (323) Diarrhoea (314) Multiple organ dysfunction syndrome (298) Polyomavirus-associated nephropathy (298)

What Other Drugs Cause Hypophosphataemia?

FERRIC CARBOXYMALTOSE (1,046) ADEFOVIR DIPIVOXIL (368) DENOSUMAB (322) ZOLEDRONIC ACID (235) LAMIVUDINE (205) CYCLOPHOSPHAMIDE (196) TENOFOVIR DISOPROXIL (192) DEXAMETHASONE (186) ACETAMINOPHEN (169) LANSOPRAZOLE (159)

Which BASILIXIMAB Alternatives Have Lower Hypophosphataemia Risk?

BASILIXIMAB vs BAYER GENUINE ASPIRIN ORIGINAL STRENGTH BASILIXIMAB vs BAZEDOXIFENE\ESTROGENS, CONJUGATED BASILIXIMAB vs BCG VACCINE BASILIXIMAB vs BEBTELOVIMAB BASILIXIMAB vs BECLOMETHASONE

Related Pages

BASILIXIMAB Full Profile All Hypophosphataemia Reports All Drugs Causing Hypophosphataemia BASILIXIMAB Demographics